• 94% objective response rate at 15.2 months follow-up
  • 90% of patients were progression free at 12 months, with median PFS rate still to be reached
  • 70% of patients with measurable brain metastases achieved complete clearance of detectable brain tumours
  • Results support potential to address key efficacy and tolerability needs in ROS1-positive NSCLC with US regulatory submission planned in 2026